Effect of nifedipine GITS on left ventricular mass and diastolic function in severe hypertension. 1991

R A Phillips, and M Ardeljan, and S Shimabukuro, and M E Goldman, and D L Garbowit, and H B Eison, and L R Krakoff
Department of Medicine, Mount Sinai Medical Center, New York, New York 10029.

Treatment of severe hypertension is beneficial, but reversibility of target-organ damage has not been characterized. Serial studies were performed in 15 patients with severe essential hypertension (age of 56 +/- 3 years, mean +/- SEM) treated for 1 year with 60 to 150 mg/day of continuous-release nifedipine; 3 patients required 50 mg of chlorthalidone/day to lower diastolic blood pressure (BP) to less than 95 mm Hg. Left ventricular (LV) structure and function was evaluated with two-dimensional-directed M-mode echocardiography, digitized from videotape and analyzed blindly. BP was markedly reduced from 194 +/- 8/115 +/- 4 to 146 +/- 4/88 +/- 14 mm Hg (p less than 0.0001) and maintained at this level for 1 year. Posterior wall and septal LV thickness, elevated at entry (12.9 +/- 0.1 and 13.4 +/- 0.1 mm), dropped steadily over 1 year into the normal range (10.0 +/- 0.03 and 11.2 +/- 0.1 mm, p less than 0.001). LV mass index, above 95% for normals at entry, decreased by 19% at 6 months (129 +/- 10 to 104 +/- 7 g/m2, p less than 0.01), and remained at this level at 1 year. LV fractional shortening rose steadily over 1 year from 34 to 42% (p less than 0.02). Atrial natriuretic peptide, which reflects LV filling pressures, was markedly elevated at entry, but was significantly reduced by 6 months (76 +/- 22 vs. 45 +/- 14 pg/ml, p less than 0.05). Sustained reduction of arterial BP with continuous-release nifedipine for 1 year normalizes LV mass, improves LV systolic function, and reduces circulating levels of atrial natriuretic peptide.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009543 Nifedipine A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure. Adalat,BAY-a-1040,Bay-1040,Cordipin,Cordipine,Corinfar,Fenigidin,Korinfar,Nifangin,Nifedipine Monohydrochloride,Nifedipine-GTIS,Procardia,Procardia XL,Vascard,BAY a 1040,BAYa1040,Bay 1040,Bay1040,Monohydrochloride, Nifedipine,Nifedipine GTIS
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D016276 Ventricular Function The hemodynamic and electrophysiological action of the HEART VENTRICLES. Function, Ventricular,Functions, Ventricular,Ventricular Functions

Related Publications

R A Phillips, and M Ardeljan, and S Shimabukuro, and M E Goldman, and D L Garbowit, and H B Eison, and L R Krakoff
August 1990, Cardiovascular drugs and therapy,
R A Phillips, and M Ardeljan, and S Shimabukuro, and M E Goldman, and D L Garbowit, and H B Eison, and L R Krakoff
June 1984, Journal of the American College of Cardiology,
R A Phillips, and M Ardeljan, and S Shimabukuro, and M E Goldman, and D L Garbowit, and H B Eison, and L R Krakoff
October 1990, Lancet (London, England),
R A Phillips, and M Ardeljan, and S Shimabukuro, and M E Goldman, and D L Garbowit, and H B Eison, and L R Krakoff
February 1992, Zhonghua xin xue guan bing za zhi,
R A Phillips, and M Ardeljan, and S Shimabukuro, and M E Goldman, and D L Garbowit, and H B Eison, and L R Krakoff
December 1989, Mayo Clinic proceedings,
R A Phillips, and M Ardeljan, and S Shimabukuro, and M E Goldman, and D L Garbowit, and H B Eison, and L R Krakoff
November 1995, Cardiology clinics,
R A Phillips, and M Ardeljan, and S Shimabukuro, and M E Goldman, and D L Garbowit, and H B Eison, and L R Krakoff
January 2004, Blood pressure,
R A Phillips, and M Ardeljan, and S Shimabukuro, and M E Goldman, and D L Garbowit, and H B Eison, and L R Krakoff
January 1993, Advances in internal medicine,
R A Phillips, and M Ardeljan, and S Shimabukuro, and M E Goldman, and D L Garbowit, and H B Eison, and L R Krakoff
April 2000, Journal of human hypertension,
R A Phillips, and M Ardeljan, and S Shimabukuro, and M E Goldman, and D L Garbowit, and H B Eison, and L R Krakoff
July 1995, Polskie Archiwum Medycyny Wewnetrznej,
Copied contents to your clipboard!